Anpac Bio Medical Science Co Ltd
Anpac Bio Medical Science — IPO Roadshow (December 2019)
34 slides from Anpac Bio Medical Science's IPO roadshow presentation, Dec 5, 2019
Slide 1: The best way to beat cancer is to catch it early
The best way to beat cancer is to catch it early. Advancing cancer screening with CDA technology and multi-disciplinary expertise. December 2019 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No: 333-234408 December 5, 2019
Slide 2: Free Writing Prospectus Disclosure
Free Writing Prospectus Disclosure AnPac Bio-Medical Science Co., Ltd., or the Company, has filed a registration statement on Form F-1 (including a prospectus) with the Securities and Exchange Commission, or the SEC, for the offering to which this free writing prospectus relates. Before you invest,
Slide 3: Transaction Overview
Transaction Overview Issuer AnPac Bio Technology Exchange/Proposed Ticker Nasdaq/ANPC Maximum Offering Size and Over-Allotment $23.3 MM Plus 15% Offering Type Class A Ordinary Shares represented by ADSs Price Range $12.00 - $14.00 / ADS Use of Proceeds Approximately 30% for research studies in China
Slide 4: Early Cancer Screening and Detection Saves Lives and Reduces Costs
Early Cancer Screening and Detection Saves Lives and Reduces Costs 18M New cases of cancer worldwide in 2018 Because early cancer screening and detection potentially shifts cancer diagnosis and treatment to earlier stages of the disease, it can improve patients’ treatment outcomes. 20.4M Expected to
Slide 5: Executive Profiles
Executive Profiles Dr. Yu has enjoyed a successful career as an innovator in semi-conductor, materials and life sciences. Worked for three U.S. Fortune 500. First or principal Inventor of over 300 patent applications spanning semiconductor, materials and life science. Proven history developing innov
Slide 6: Overview
Overview Early cancer screening saves lives and dramatically reduces costs. AnPac Bio is a biotechnology company focusing on a new technology for early cancer screening and detection. AnPac Bio’s technology is a multi-cancer screening and detection test that uses innovative, patented Cancer Differen
Slide 7: Key Facts
Key Facts 2010 Founded in 101 Employees* ~140K General population screening & research study blood samples 2 clinical laboratories in China* 210 patent applications globally (including 121 issued)* 121 patents issued* 1st in 2018 volume of next generation commercial cancer screening and detection te
Slide 8: Overview Cont.
Overview Cont. AnPac Bio’s 101 employees comprise creative and innovative scientists, researchers, engineers, and business professionals in China and the U.S.. Educated at internationally-acclaimed, universities and educational institutions (such as Yale University); and recruited from Fortune 500,
Slide 9: CDA Technology
CDA Technology
Slide 10: Cancer Differentiation Analysis (CDA)
Cancer Differentiation Analysis (CDA) A multi-cancer screening test and analysis platform to detect and assess overall cancer risk. CDA analyzes biophysical properties in human blood. Research shows a correlation between biophysical properties (acoustical, electrical, magnetic, nano-mechanical and o
Slide 11: CDA Testing Process
CDA Testing Process Fully Automated Cancer Detection Device from Sample to Data Report Blood Sample Sample preparation Detection using sensors Sample discharge and cleaning Data transfer and processing Heating and/or adding reagent(s) (optional) Multi-parameter detection at various levels including
Slide 12: Winning the China Market
Winning the China Market Employer-provided annual physicals are very common in China. $27.7B In 2014 $58.8B In 2018 $115.1B In 2023 20.7% Increase Expected to reach Based on China’s large population, the market potential in China for early cancer screening and detection technologies increased at a C
Slide 13: Target Markets & Competitive Landscape
Target Markets & Competitive Landscape Application for CDA Technology: AnPac Bio is applicable at all points throughout the cycle. Screening Assisting Diagnosis Prognosis | Therapy Selection Recurrence Monitoring Many other liquid-based cancer screening and detection technologies focus on biochemica
Slide 14: U.S. Penetration Roadmap
U.S. Penetration Roadmap Established major U.S. research partners San Jose Lab CLIA Certification 2nd Lab to be established in Pennsylvania in 2020 Sometime in 2020, we plan to begin marketing our CDA-based test as a laboratory-developed test, or LDT in the U.S. Awarded the Minority Health Products
Slide 15: Meta-Analysis CDA Data on Various Types of Cancer
Meta-Analysis CDA Data on Various Types of Cancer* Breast Cancer (493) Sen.: 74.6%, Spec.: 92.2% Liver Cancer (804) Sen.: 92.3%, Spec.: 93.2% Cerebral Cancer (93) Sen.: 89.2%, Spec.: 89.9% Lung Cancer (2,277) Sen.: 82.4%, Spec.: 83.0% Pancreatic Cancer (162) Sen.: 89.3%, Spec.: 90.6% Prostatic Cance
Slide 16: Case Studies
Case Studies *As of October 25, 2019, we had contacted over 12,000 tested individuals. Based on the feedback from these calls, around 889 of the tested individuals had been diagnosed with various major diseases or cancers by third-party hospitals and medical institutions within two years of taking o
Slide 17: Prognosis & Follow-up Data of CDA Values
Prognosis & Follow-up Data of CDA Values We tracked a number of patients throughout their approximately three years of cancer treatment. The graph illustrates the changes of a representative patient’s CDA values throughout the tracking period. CDA in Long-Term Cancer Monitoring (Stage IIA Lung Cance
Slide 18: Retrospective Studies & Published Work
Retrospective Studies & Published Work 2015 ASCO Annual Meeting, J Clin Oncol 33, e12578, 2015 (co-author: Cancer Hospital of Chinese Academy of Medical Sciences) 2015 Nobel Prize Laureate Summit on Biomedical Sciences (co-authors: Shanghai Changhai Hospital and School of Life Science of Fudan Unive
Slide 19: Competitive Advantages
Competitive Advantages We believe that the advantages of our CDA technology summarized below can help us seize the tremendous market opportunity: Numerous research studies have demonstrated our CDA technology’s ability to detect early-stage cancers with high sensitivity and specificity rates, includ
Slide 20: Financial Summary
Financial Summary
Slide 21: Financial Profile 2018 YOY Financial Growth
Financial Profile 2018 YOY Financial Growth +80.3% +115.2% +80% From 2017 to 2018 Revenue growth *Represents total commercial tests
Slide 22: Financial Profile 9 Months Ended 9/30 2018 vs. 2019
Financial Profile 9 months Ended 9/30 2018 vs. 2019 Growth +43.1% +22.3% From 9 months ended September 30, 2018 to 9 months ended September 30, 2019 Revenue growth *Represents total commercial tests +22.3%
Slide 23: Financial Highlights
Financial Highlights Financial Snapshot (000’s) % Growth Revenues (RMB) FYE 2017 vs. 2018 ¥5,686 ¥10,250 80.3% 9/30 2018 vs. 2019 ¥6,631 ¥8,113 22.3% Commercial Paid Tests FYE 2017 vs. 2018 19,336 41,607 115.2% 9/30 2018 vs. 2019 29,036 41,544 43.1% Gross Profit Margin FYE 2017 vs. 2018 30.5% 44.7%
Slide 24: Summary Financial Data
Summary Financial Data 1. The increase from the nine months ended September 30, 2018 to the same period of 2019 was due primarily to an increase in share-based compensation and an increase in professional service fees, mainly related to this offering. Financial Snapshot (000’s) FYE 12/31 9 Months En
Slide 25: Slide 25
Slide 26: Exhibits
Exhibits
Slide 27: Exhibit: Patent Detail
Exhibit: Patent Detail* 210 Patent applications filed globally (including 121 issued) 20 Countries and regions 121 Patents have been issued nearly *As of September 30, 2019 ***According to our public searches, some of our patents, including our newly issued U.S. patents, have been cited by patent ex
Slide 28: Current Situation of Cancer Diagnosis & Significance of Early Detection in China
Current Situation of Cancer Diagnosis & Significance of Early Detection in China Certain cancer types, such as breast and cervix cancer have a higher possibility of being diagnosed at an early stage due to the implementation of screening programs, and the proportion of patients being diagnosed at th
Slide 29: Clinical Scenarios of Cancer Diagnosis across the Care Continuum
Clinical Scenarios of Cancer Diagnosis across the Care Continuum Source: Frost & Sullivan analysis Early cancer screening and detection Therapy selection Treatment monitoring/ relapse management Target population in China in 2018 Asymptomatic population at heightened risk of cancer (e.g., due to age
Slide 30: Screening Programs for Cancer
Screening Programs for Cancer Many countries have established screening programs in place for cancers with the highest incidence, in an effort to detect cancers in asymptomatic populations. Source: Globocan, IARC, USPSTF, Frost & Sullivan Analysis Global Incidence in 2018 (Thousand) Available screen
Slide 31: Exhibit: Use of Funds
Exhibit: Use of Funds We require substantial capital to expand our business, pursue strategic investments and for other reasons, including to: increase our sales and marketing efforts to drive market adoption of our cancer screening and detection tests and address competitive developments; expand ou
Slide 32: Exhibit: Competitor Matrix
CRC Stomach Breast Liver Cervix Lung Esophagus Company A AnPac Company B Company C Company D CRC Prostate Breast Liver Pancreas Lung Kidney Ovarian Cervical Gastric Oesophageal NPC & Lymphoma, MElanoma GRAIL Guardant Health Singlera Genomics Exact Sciences Freenome Owlstone Medical Anchor Dx Natera*
Slide 33: Exhibit: Validation & Studies
Exhibit: Validation & Studies We have conducted substantial research studies on our CDA technology’s utility and accuracy. Since 2015, we have completed 15 research studies on our CDA technology with five hospitals and medical institutes in China. We have published the results of these studies at im
Slide 34: Exhibit: Validation & Studies
Exhibit: Validation & Studies Set forth below are several representative examples of validation studies on our CDA technology that we have completed with Chinese hospitals: Since 2015, we have cooperated with Shanghai Changhai Hospital to research various cancers, including lung cancer. We have publ
AnPac Bio-Medical Science — IPO Roadshow (December 2019) on 6ix